Open Targets Platform: new developments and updates two years on
Open Targets Platform: new developments and updates two years on
复制标题
DOI：
10.1093/nar/gky1133
复制
发表时间：
2019-01-08
影响因子：
14.9
通讯作者：
Dunham, Ian
中科院分区：
文献类型：
--
作者：
Carvalho-Silva, Denise;Pierleoni, Andrea;Dunham, Ian
开放靶标平台整合了来自遗传学、基因组学、转录组学、药物、动物模型和科学文献的证据，对药物靶标识别的靶标-疾病关联进行评分和排名。关联显示在直观的用户界面（https：//www.example.com）中，并可通过REST-API（https：//api.opentargets.io/v3/platform/docs/swagger-ui）和批量下载（https：//www.targetvalidation.org/downloads/data）获得。www.targetvalidation.org除了目标-疾病关联外，我们还在目标和疾病水平上汇总和显示数据，以帮助确定目标优先级。自两年前首次发表以来，我们已经发布了八个版本，为目标-疾病关联增加了新的数据源，开始包括来自非全基因组靶向阵列的因果遗传变异，增加了新的目标和疾病注释，推出了新的可视化并改进了现有的可视化，并发布了一个新的Web工具，用于批量搜索多达200个目标。我们为开放目标平台REST-API提供了一个新的URL，新的REST端点，并且还删除了API合理使用的授权需求。在这里，我们介绍了开放目标平台的最新发展，通过新的和改进的数据源扩大证据和目标疾病关联，改进数据质量，提高网站可用性，并通过我们的培训研讨会，用户支持，社交媒体和生物信息学论坛参与增加我们的用户群。
The Open Targets Platform integrates evidence from genetics, genomics, transcriptomics, drugs, animal models and scientific literature to score and rank target-disease associations for drug target identification. The associations are displayed in an intuitive user interface (https://www.targetvalidation.org), and are available through a REST-API (https://api.opentargets.io/v3/platform/docs/swagger-ui) and a bulk download (https://www.targetvalidation.org/downloads/data). In addition to target-disease associations, we also aggregate and display data at the target and disease levels to aid target prioritisation. Since our first publication two years ago, we have made eight releases, added new data sources for target-disease associations, started including causal genetic variants from non genome-wide targeted arrays, added new target and disease annotations, launched new visualisations and improved existing ones and released a new web tool for batch search of up to 200 targets. We have a new URL for the Open Targets Platform REST-API, new REST endpoints and also removed the need for authorisation for API fair use. Here, we present the latest developments of the Open Targets Platform, expanding the evidence and target-disease associations with new and improved data sources, refining data quality, enhancing website usability, and increasing our user base with our training workshops, user support, social media and bioinformatics forum engagement.